Impact of GLP-1 Analogue Therapy on Gastrointestinal Outcomes in Patients with Irritable Bowel Syndrome: A Real-World TriNetX Analysis.
GLP-1 receptor agonists were associated with lower rates of gastrointestinal symptoms in IBS patients, but these findings need further investigation.
Where it sits
this study against the rest of the exenatide corpusSummary and findings
This study evaluated the association between GLP-1 receptor agonist initiation and gastrointestinal outcomes in patients with irritable bowel syndrome (IBS). The analysis included patients who initiated therapy within 30 or 90 days after IBS diagnosis. The findings indicated lower rates of gastrointestinal symptoms in the GLP-1 group compared to non-GLP-1 controls.
Abstract
<h4>Background</h4>Glucagon-like peptide-1 (GLP-1) receptor agonists are increasingly prescribed for diabetes and obesity, conditions that frequently coexist with irritable bowel syndrome (IBS). Their effects on gastrointestinal motility and visceral sensitivity raise the possibility of therapeutic benefit in IBS, but real-world evidence remains limited. This study evaluated the association between GLP-1 receptor agonist initiation and subsequent gastrointestinal outcomes in patients with IBS using a large federated electronic health records network.<h4>Methods</h4>We conducted a retrospective cohort study using the TriNetX Research Network. Patients with IBS (ICD-10 K58) who initiated GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide, exenatide, or tirzepatide) within 30 or 90 days after IBS diagnosis (GLP-1 group) were propensity score matched to IBS patients who did not receive GLP-1 therapy (non-GLP-1 group). Analyses were performed for the overall IBS cohort and stratified by subtype (IBS-D [K58.0] and IBS-C [K58.1]). Outcomes included coded chronic diarrhea, chronic constipation, abdominal pain, malabsorption, and abdominal bloating/distension. Incident outcomes were assessed using risk ratios, hazard ratios from Kaplan-Meier survival analysis, and log-rank tests.<h4>Results</h4>After matching, the 30-day landmark cohort included 4,668 patients per group and the 90-day landmark cohort included 6,665 patients per group. In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%), chronic constipation (19.8% vs. 22.0%), abdominal pain (31.6% vs. 35.8%), and abdominal bloating/distension (8.3% vs. 10.9%) compared with non-GLP-1 controls (all p < 0.001). Similar reductions were observed in IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension. Differences in outcome recurrence (number of instances) were smaller than differences in incidence.<h4>Conclusions</h4>Initiation of GLP-1 receptor agonists was associated with significantly lower rates of several coded gastrointestinal symptoms in patients with IBS across multiple landmark periods and subtypes. While these observational findings are hypothesis-generating and require confirmation in prospective studies, they suggest potential benefit of GLP-1 therapies on IBS-related outcomes.
Background
This paper addresses the potential effects of GLP-1 receptor agonists on gastrointestinal outcomes in patients with irritable bowel syndrome (IBS). Prior research has suggested that GLP-1 receptor agonists may influence gastrointestinal motility and visceral sensitivity. This study is significant as it utilizes a large electronic health records network to evaluate real-world outcomes associated with GLP-1 therapy in IBS patients.
Methods
A retrospective cohort study was conducted using the TriNetX Research Network. Patients with IBS who initiated GLP-1 receptor agonists within 30 or 90 days after diagnosis were matched to those who did not receive GLP-1 therapy. The primary outcomes included coded chronic diarrhea, chronic constipation, abdominal pain, malabsorption, and abdominal bloating/distension, assessed using risk ratios and hazard ratios from Kaplan-Meier survival analysis.
Results
In the 90-day analysis, GLP-1 use was associated with significantly lower rates of chronic diarrhea (8.9% vs. 10.6%, p<0.001), chronic constipation (19.8% vs. 22.0%, p<0.001), abdominal pain (31.6% vs. 35.8%, p<0.001), and abdominal bloating/distension (8.3% vs. 10.9%, p<0.001) compared to non-GLP-1 controls. Similar reductions were observed in both IBS-D and IBS-C subtypes, particularly for abdominal pain and bloating/distension.
Interpretation
The findings suggest a potential association between GLP-1 receptor agonist therapy and improved gastrointestinal symptoms in IBS patients. However, while the results are statistically significant, the clinical significance of the observed effect sizes may be limited. The study's observational nature and reliance on electronic health records introduce potential confounding factors that could affect the validity of the conclusions.
Key findings
- 8.9% chronic diarrhea vs 10.6% in non-GLP-1 group at 90 days, p<0.001.
- 19.8% chronic constipation vs 22.0% in non-GLP-1 group at 90 days, p<0.001.
- 31.6% abdominal pain vs 35.8% in non-GLP-1 group at 90 days, p<0.001.
- 8.3% abdominal bloating/distension vs 10.9% in non-GLP-1 group at 90 days, p<0.001.
- 4,668 patients per group in the 30-day cohort.
- 6,665 patients per group in the 90-day cohort.
Limitations
- observational study design
- relies on electronic health records
- hypothesis-generating findings
- potential biases in data collection
- no long-term follow-up reported